Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension

Abstract Background Limited data exists regarding healthcare utilization, medical expenses, and prognosis of pulmonary hypertension (PH) according to the World Health Organization (WHO) classification. We aimed to investigate mortality risk, healthcare utilization and medical expenditure in patients...

Full description

Bibliographic Details
Main Authors: In-Chang Hwang, Goo-Yeong Cho, Hong-Mi Choi, Yeonyee E. Yoon, Jin Joo Park, Jun-Bean Park, Seung-Pyo Lee, Hyung-Kwan Kim, Yong-Jin Kim, Dae-Won Sohn
Format: Article
Language:English
Published: BMC 2019-10-01
Series:BMC Pulmonary Medicine
Subjects:
Online Access:http://link.springer.com/article/10.1186/s12890-019-0945-0
id doaj-505b2731084343dfa212790e9eb1a1c8
record_format Article
spelling doaj-505b2731084343dfa212790e9eb1a1c82020-11-25T04:00:58ZengBMCBMC Pulmonary Medicine1471-24662019-10-0119111110.1186/s12890-019-0945-0Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertensionIn-Chang Hwang0Goo-Yeong Cho1Hong-Mi Choi2Yeonyee E. Yoon3Jin Joo Park4Jun-Bean Park5Seung-Pyo Lee6Hyung-Kwan Kim7Yong-Jin Kim8Dae-Won Sohn9Department of Cardiology, Cardiovascular Center, Seoul National University Bundang HospitalDepartment of Cardiology, Cardiovascular Center, Seoul National University Bundang HospitalDivision of Cardiology, Hallym Sacred Heart Hospital, Hallym University College of MedicineDepartment of Cardiology, Cardiovascular Center, Seoul National University Bundang HospitalDepartment of Cardiology, Cardiovascular Center, Seoul National University Bundang HospitalDepartment of Internal Medicine, Seoul National University College of MedicineDepartment of Internal Medicine, Seoul National University College of MedicineDepartment of Internal Medicine, Seoul National University College of MedicineDepartment of Internal Medicine, Seoul National University College of MedicineDepartment of Internal Medicine, Seoul National University College of MedicineAbstract Background Limited data exists regarding healthcare utilization, medical expenses, and prognosis of pulmonary hypertension (PH) according to the World Health Organization (WHO) classification. We aimed to investigate mortality risk, healthcare utilization and medical expenditure in patients with PH across the five diagnostic subgroups. Methods We identified 2185 patients with PH, defined as peak tricuspid regurgitation velocity > 3.4 m/sec, among the consecutive patients referred for echocardiography between 2009 and 2015. Using diagnostic codes, medical records, and echocardiographic findings, the enrolled patients were classified according to the five subgroups by WHO classification. Healthcare utilization, costs, and all-cause mortality were assessed. Results Diagnostic subgroups of PH demonstrated significantly different clinical features. During a median of 32.4 months (interquartile range, 16.2–57.8), 749 patients (34.3%) died. Mortality risk was the lowest in group II (left heart disease) and highest in group III (chronic lung disease). The etiologies of pulmonary arterial hypertension (PAH) had significant influence on the mortality risk in group I, showing the worst prognosis in PAH associated with connective tissue disease. Medical expenditure and healthcare utilization were different between the PH subgroups: groups II and V had more hospitalizations and medical expenses than other groups. Regardless of PH subgroups, the severity of PH was associated with higher mortality risk, more healthcare utilization and medical expenditure. Conclusions Significant differences in clinical features and prognostic profiles between PH subgroups reflect the differences in pathophysiology and clinical consequences. Our findings highlight the importance of comprehensive understanding of PH according to the etiology and its severity.http://link.springer.com/article/10.1186/s12890-019-0945-0Pulmonary hypertensionHealthcare utilizationMortality
collection DOAJ
language English
format Article
sources DOAJ
author In-Chang Hwang
Goo-Yeong Cho
Hong-Mi Choi
Yeonyee E. Yoon
Jin Joo Park
Jun-Bean Park
Seung-Pyo Lee
Hyung-Kwan Kim
Yong-Jin Kim
Dae-Won Sohn
spellingShingle In-Chang Hwang
Goo-Yeong Cho
Hong-Mi Choi
Yeonyee E. Yoon
Jin Joo Park
Jun-Bean Park
Seung-Pyo Lee
Hyung-Kwan Kim
Yong-Jin Kim
Dae-Won Sohn
Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension
BMC Pulmonary Medicine
Pulmonary hypertension
Healthcare utilization
Mortality
author_facet In-Chang Hwang
Goo-Yeong Cho
Hong-Mi Choi
Yeonyee E. Yoon
Jin Joo Park
Jun-Bean Park
Seung-Pyo Lee
Hyung-Kwan Kim
Yong-Jin Kim
Dae-Won Sohn
author_sort In-Chang Hwang
title Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension
title_short Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension
title_full Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension
title_fullStr Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension
title_full_unstemmed Healthcare utilization, medical expenditure, and mortality in Korean patients with pulmonary hypertension
title_sort healthcare utilization, medical expenditure, and mortality in korean patients with pulmonary hypertension
publisher BMC
series BMC Pulmonary Medicine
issn 1471-2466
publishDate 2019-10-01
description Abstract Background Limited data exists regarding healthcare utilization, medical expenses, and prognosis of pulmonary hypertension (PH) according to the World Health Organization (WHO) classification. We aimed to investigate mortality risk, healthcare utilization and medical expenditure in patients with PH across the five diagnostic subgroups. Methods We identified 2185 patients with PH, defined as peak tricuspid regurgitation velocity > 3.4 m/sec, among the consecutive patients referred for echocardiography between 2009 and 2015. Using diagnostic codes, medical records, and echocardiographic findings, the enrolled patients were classified according to the five subgroups by WHO classification. Healthcare utilization, costs, and all-cause mortality were assessed. Results Diagnostic subgroups of PH demonstrated significantly different clinical features. During a median of 32.4 months (interquartile range, 16.2–57.8), 749 patients (34.3%) died. Mortality risk was the lowest in group II (left heart disease) and highest in group III (chronic lung disease). The etiologies of pulmonary arterial hypertension (PAH) had significant influence on the mortality risk in group I, showing the worst prognosis in PAH associated with connective tissue disease. Medical expenditure and healthcare utilization were different between the PH subgroups: groups II and V had more hospitalizations and medical expenses than other groups. Regardless of PH subgroups, the severity of PH was associated with higher mortality risk, more healthcare utilization and medical expenditure. Conclusions Significant differences in clinical features and prognostic profiles between PH subgroups reflect the differences in pathophysiology and clinical consequences. Our findings highlight the importance of comprehensive understanding of PH according to the etiology and its severity.
topic Pulmonary hypertension
Healthcare utilization
Mortality
url http://link.springer.com/article/10.1186/s12890-019-0945-0
work_keys_str_mv AT inchanghwang healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT gooyeongcho healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT hongmichoi healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT yeonyeeeyoon healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT jinjoopark healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT junbeanpark healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT seungpyolee healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT hyungkwankim healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT yongjinkim healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
AT daewonsohn healthcareutilizationmedicalexpenditureandmortalityinkoreanpatientswithpulmonaryhypertension
_version_ 1724448219985870848